C91.6 Prolymphocytic leukemia of T-cell type

Name of the Condition

• Prolymphocytic leukemia of T-cell type
• ICD-10 Code: C91.6

Summary

Prolymphocytic leukemia of T-cell type (T-PLL) is a rare, aggressive cancer of the blood and bone marrow that affects T lymphocytes, a type of white blood cell. It involves the uncontrolled proliferation of abnormal T cells, which can accumulate in the blood, bone marrow, and lymphoid tissues. T-PLL is characterized by a rapid clinical course and may involve organ infiltration, including the spleen, liver, and skin.

Causes

The exact cause of T-PLL is not fully understood, but it involves genetic mutations in T lymphocytes that disrupt normal cell regulation. Contributing factors may include chromosomal abnormalities, such as inv(14)(q11;q32) or t(14;14)(q11;q32), and alterations in genes like TCL1 or MTCP1. Unlike other leukemias, T-PLL is often associated with mature T-cell dysfunction rather than immature cell proliferation.

Risk Factors

• Increasing age (most common in adults over 60)
• Prior exposure to certain chemicals or radiation (less clearly established)
• Genetic predispositions, including inherited immune disorders
• History of other lymphoid malignancies

Symptoms

• Fatigue and weakness
• Enlarged spleen or liver
• Skin rashes or lesions
• Frequent infections due to impaired immune function
• Unexplained weight loss
• Shortness of breath or chest discomfort

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal T cells. Flow cytometry is used to confirm T-cell lineage, and cytogenetic analysis may detect characteristic chromosomal abnormalities. A bone marrow biopsy is typically performed to evaluate cell infiltration and confirm the diagnosis.

Treatment Options

Treatment may include chemotherapy regimens, such as purine analogs (e.g., cladribine, pentostatin), or monoclonal antibodies (e.g., alemtuzumab). Allogeneic stem cell transplantation may be considered for eligible patients, particularly those with refractory disease. Supportive care, including infection prevention and management of cytopenias, is also important.

Prognosis and Follow-Up

T-PLL has a poor prognosis due to its aggressive nature, with median survival often less than two years. Regular follow-up is essential to monitor disease progression, manage complications, and adjust treatment as needed. Response to therapy is typically assessed through blood counts, imaging, and bone marrow evaluations.

Complications

• Severe infections due to immune dysfunction
• Organ infiltration (e.g., spleen, liver, skin)
• Cytopenias (low blood cell counts)
• Transformation to more aggressive lymphoid malignancies
• Treatment-related toxicities

Lifestyle & Prevention

No specific preventive measures are known for T-PLL. Maintaining overall health, including a balanced diet, regular exercise, and avoiding known carcinogens (e.g., tobacco, excessive radiation), may support immune function. Patients should avoid exposure to infections and follow vaccination guidelines as recommended by their healthcare provider.

When to Seek Professional Help

Seek immediate medical attention for symptoms such as unexplained fever, severe fatigue, uncontrolled bleeding, or sudden organ enlargement. Regular follow-up with a hematologist-oncologist is recommended for patients with a history of T-PLL or related conditions.

Tips for Medical Coders

When coding for C91.6, ensure documentation specifies "prolymphocytic leukemia of T-cell type" to distinguish it from other lymphoid leukemias. Verify that the diagnosis is supported by laboratory or pathology reports confirming T-cell lineage and prolymphocytic morphology. Include any relevant clinical details, such as treatment regimens or complications, to support accurate coding and billing.